Literature DB >> 17445068

Carotid intima-media thickness in HIV patients treated with antiretroviral therapy.

Anne-Mette Lebech1, Niels Wiinberg, Ulrik Sloth Kristoffersen, Birger Hesse, Claus Leth Petersen, Jan Gerstoft, Andreas Kjaer.   

Abstract

INTRODUCTION: Increased cardiovascular risk in HIV patients in antiretroviral therapy (ART) may be due to HIV infection, direct effect of ART or dyslipidaemia induced by ART. Our aim was to study the relative importance of HIV, ART and dyslipidaemia on atherosclerosis, assessed by the comparison of carotid artery intima-media thickness (IMT) in non-smoking HIV patients with high or low serum cholesterol levels as well as in healthy volunteers.
METHODS: HIV patients in ART with normal cholesterol (<or=5 x 5 mmol l(-1); n=13) or high cholesterol (>or=6 x 5 mmol l(-1); n=12) as well as healthy controls (n=14) were included. All were non-smokers and had never received medication for dyslipidaemia or hypertension. IMT was measured by ultrasonography.
RESULTS: In HIV patients with normal cholesterol (<or=5 x 5 mmol l(-1)), in HIV patients with hypercholesterolaemia (>or=6 x 5 mmol l(-1)) and in controls (5 x 1 +/- 0 x 9 mmol l(-1)) IMT were 683 +/- 119, 656 +/- 99 and 657 +/- 99 microm, respectively. Thus no difference in IMT was found between the three groups. IMT values did not differ between patients receiving and not receiving protease inhibitors (658 +/- 117 microm versus 687 +/- 97 microm, P>0 x 05). In HIV patients IMT correlated inversely with HDL cholesterol levels (r=-0 x 50; P=0 x 01), whereas no correlation was found with total cholesterol or LDL cholesterol.
CONCLUSIONS: In non-smoking HIV patients receiving ART no sign of accelerated atherosclerosis was found as assessed by IMT even not in hypercholesterolaemic HIV patients. IMT correlated with HDL cholesterol but not with LDL cholesterol. Based on these observations, one could speculate whether selective lowering of LDL cholesterol will be successful in reducing cardiovascular risk in non-smoking HIV patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17445068     DOI: 10.1111/j.1475-097X.2007.00737.x

Source DB:  PubMed          Journal:  Clin Physiol Funct Imaging        ISSN: 1475-0961            Impact factor:   2.273


  3 in total

1.  The aggregate effects of multiple comorbid risk factors on cognition among HIV-infected individuals.

Authors:  Sapna M Patel; April D Thames; Natalie Arbid; Stella E Panos; Steven Castellon; Charles H Hinkin
Journal:  J Clin Exp Neuropsychol       Date:  2013-04-03       Impact factor: 2.475

2.  Neurocognitive functioning in HIV-1 infection: effects of cerebrovascular risk factors and age.

Authors:  Jessica Foley; Mark Ettenhofer; Matthew J Wright; Iraj Siddiqi; Melissa Choi; April D Thames; Karen Mason; Steven Castellon; Charles H Hinkin
Journal:  Clin Neuropsychol       Date:  2010-02       Impact factor: 3.535

3.  Silent ischemic heart disease and pericardial fat volume in HIV-infected patients: a case-control myocardial perfusion scintigraphy study.

Authors:  Ulrik S Kristoffersen; Anne-Mette Lebech; Niels Wiinberg; Claus L Petersen; Philip Hasbak; Henrik Gutte; Gorm B Jensen; Anne Mette F Hag; Rasmus S Ripa; Andreas Kjaer
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.